At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his stud yon radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his stud yon radiation therapy vs radiation therapy plus radiofrequency ablation.
Kyle S. Stumetz, DO, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, DO, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
These cases were part of the Instylla HES Hypervascular Tumor Pivotal Study to evaluate the safety and effectiveness of Embrace HES compared with standard of care TAE or TACE.
These cases were part of the Instylla HES Hypervascular Tumor Pivotal Study to evaluate the safety and effectiveness of Embrace HES compared with standard of care TAE or TACE.
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Jason Levy, MD, FSIR, discusses the clinical considerations, procedural techniques, and ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Jason Levy, MD, FSIR, discusses the clinical considerations, procedural techniques, and ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Dr Jason Levy discusses the clinical considerations, procedural techniques, and the ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Dr Jason Levy discusses the clinical considerations, procedural techniques, and the ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Dr Heather McArthur speaks about her work examining the impact of perioperative cryoablation and immune checkpoint inhibition on 3-year event-free survival in women with TNBC after taxane-based neoadjuvant chemotherapy.
Dr Heather McArthur speaks about her work examining the impact of perioperative cryoablation and immune checkpoint inhibition on 3-year event-free survival in women with TNBC after taxane-based neoadjuvant chemotherapy.
Ahead of SIR 2025, Dr Setayesh Sotoudehnia of Mayo Clinic Rochester speaks about her research on MR-guided procedures, her GCAW Award, and the advancement of women in the field of interventional radiology.
Ahead of SIR 2025, Dr Setayesh Sotoudehnia of Mayo Clinic Rochester speaks about her research on MR-guided procedures, her GCAW Award, and the advancement of women in the field of interventional radiology.
In this video from ISET2025, interventional radiologist Dr Nainesh Parikh discusses his presentation on the benefits of prostatic artery embolization in the treatment of prostate cancer.
In this video from ISET2025, interventional radiologist Dr Nainesh Parikh discusses his presentation on the benefits of prostatic artery embolization in the treatment of prostate cancer.
Dr KJ Nagarsheth, Professor of Surgery, Division of Vascular Surgery, at the University of Maryland School of Medicine, offers a concise, real-world readout on the clinical and procedural value of the Artix thrombectomy system.
Dr KJ Nagarsheth, Professor of Surgery, Division of Vascular Surgery, at the University of Maryland School of Medicine, offers a concise, real-world readout on the clinical and procedural value of the Artix thrombectomy system.
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his stud yon radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his stud yon radiation therapy vs radiation therapy plus radiofrequency ablation.
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
Bruno C. Odisio, MD, PhD, FSIR, FCIRSE; Iwan Paolucci, PhD
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his stud yon radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his stud yon radiation therapy vs radiation therapy plus radiofrequency ablation.
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
Bruno C. Odisio, MD, PhD, FSIR, FCIRSE; Iwan Paolucci, PhD
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
BEDFORD, Mass., Aug. 7, 2025 /PRNewswire/ -- Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval (PMA) from the U.S. Food and Drug Administration...
BEDFORD, Mass., Aug. 7, 2025 /PRNewswire/ -- Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval (PMA) from the U.S. Food and Drug Administration...
SUNNYVALE, Calif., July 28, 2025 /PRNewswire/ -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third...
SUNNYVALE, Calif., July 28, 2025 /PRNewswire/ -- Embolx, a leader in advanced microcatheters for targeted embolization procedures, today announced the release of its next-generation Sniper G3 Balloon Occlusion Microcatheter. This third...
BEDFORD, Mass., March 11, 2025 /PRNewswire/ -- Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration...
BEDFORD, Mass., March 11, 2025 /PRNewswire/ -- Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration...
Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System.
Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System.
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio
LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio
LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular
BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional...
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular
BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional...
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients.
FLAGSTAFF, Ariz. (January 6, 2026) — W. L. Gore & Associates’...
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients.
FLAGSTAFF, Ariz. (January 6, 2026) — W. L. Gore & Associates’...
MIDWAY 43 and MIDWAY 62 delivery catheters are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature.
MIDWAY 43 and MIDWAY 62 delivery catheters are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature.
The research suggests that CAVT, a technology designed to rapidly remove blood clots via microprocessor-controlled aspiration, has the potential to help reduce healthcare costs.
The research suggests that CAVT, a technology designed to rapidly remove blood clots via microprocessor-controlled aspiration, has the potential to help reduce healthcare costs.
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled...
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled...
The first pivotal trial implant of an investigational endovascular stent graft for the treatment of acute Type A dissections marks a critical milestone.
The first pivotal trial implant of an investigational endovascular stent graft for the treatment of acute Type A dissections marks a critical milestone.
